Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Study: Screen Hospitalized Lupus Patients for Venous Thromboembolism

Catherine Kolonko  |  Issue: September 2019  |  September 17, 2019

Dr. Kishore‘The whole point is that [lupus patients] are at a higher risk of developing a thromboembolism, so they should be considered for prophylactic anticoagulation.’ —Dr. Kishore

Consider VTE Prophylaxis

It is well known by physicians nationwide that patients are at risk for VTE if they are admitted to a hospital, regardless of whether they have lupus, Dr. Kishore says. Nevertheless, findings from several studies suggest patients at risk are not always given VTE prophylaxis while they are in the hospital, which leads to even higher mortality or a longer length of stay for lupus patients, she says.

Dr. Majithia

Dr. Majithia

“The whole point is that [lupus patients] are at a higher risk of developing a thromboembolism so they should be considered for prophylactic anticoagulation,” Dr. Kishore says.

Factors that contribute to an increased risk of VTE for lupus patients include antiphospholipid antibody syndrome, chronic inflammation, kidney involvement and steroid treatment leading to sluggish blood flow. These patients also have a higher risk of developing diabetes, high cholesterol and high blood pressure, which can increase the risk of blood clots, Dr. Kishore says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The study authors recommend hospitalized patients with lupus be screened for VTE and offered prophylactic anticoagulation to reduce the risk of thromboembolism. Education and further study on the risk for VTE, symptom monitoring and the development of a prophylactic strategy for hospitalized lupus patients are also needed, says Dr. Kishore.

“It’s very important rheumatologists be aware of these findings and educate other physicians in their community,” she says.


Catherine Kolonko is a medical writer based in Oregon.

Reference

  1. Kishore S, Jatwani S, Malhotra B, et al. Systemic lupus erythematosus is associated with a high risk of venous thromboembolism in hospitalized patients leading to poor outcomes and a higher cost: Results from nationwide inpatient sample database 2003–2011. ACR Open Rheumatology. 2019 May 13;1(3):194–200.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:mortality riskvenous thromboembolism

Related Articles

    Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

    October 7, 2020

    An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

    Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

    Antiphospholipid Syndrome: The Risk of Travel at High Altitudes

    August 16, 2018

    Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long…

    Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

    December 1, 2022

    PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

    Rheumatology Case Report: Deep Vein Thrombosis Detected by Point-of-Care Ultrasound

    April 18, 2017

    Case A 46-year-old Caucasian female presented to the outpatient rheumatology clinic where she had been followed for several years. Her chief complaint was pain in her right knee, posterior right thigh and right hip that had begun gradually over the previous three weeks. Her past medical history was significant for rheumatoid arthritis (RA), obesity and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences